Phase II study of CHOP-GR therapy in diffuse large B-cell lymphoma

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Standard treatment protocols require optimization for improved patient outcomes.
• Combination chemotherapy regimens are a cornerstone of DLBCL treatment.

Purpose of the Study:

• To evaluate the safety and efficacy of a novel combination chemotherapy protocol (CHOP-GR) in patients with untreated DLBCL.
• To assess treatment response rates, survival outcomes, and adverse events associated with the CHOP-GR regimen.
• To determine the suitability of CHOP-GR for different patient risk groups based on age and International Prognostic Index (IPI).

Main Methods:

• A phase II clinical trial was conducted involving 44 patients with untreated DLBCL.
• Patients received two courses of CHOP chemotherapy followed by four courses of CHOP-GR.
• CHOP-GR included granulocyte colony-stimulating factor (G-CSF) and rituximab, with additional weekly rituximab courses.

Main Results:

• Complete remission was achieved in 91% of assessable patients (39 out of 43).
• The 5-year overall survival rate was 77%, and the 5-year progression-free survival rate was 69%.
• Common adverse events included leukocytopenia (98%), neutropenia (94%), and lymphocytopenia (91%).

Conclusions:

• The CHOP-GR regimen is a safe and effective therapeutic option for patients with untreated DLBCL.
• The observed survival rates and remission rates suggest a favorable risk-benefit profile for CHOP-GR.
• Further investigation into CHOP-GR may support its integration into standard DLBCL treatment guidelines.